Is Cencora, Inc. (COR) a Buy, Sell, or Hold?
Cencora, Inc.
NYSE:COR
$296.57 USD
-$5.71 (-1.89%)
- Volume
- 811.84K
- Average Volume
- 1.83M
- Market Capitalization
- $57.7B
- P/E Ratio
- 22.60
- Dividend Yield
- 0.79%
- Price Target
- $355.00
- Year High
- $377.54
- Year Low
- $244.82
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.18
- Current Ratio
- $0.95
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Robert Mauch |
| Industry | Medical - Distribution |
| Sector | Healthcare |
| Current Symbol | COR |
| CUSIP | 03073E105 |
| CIK | 0001140859 |
| Web | https://www.cencora.com |
| Phone | 610 727 7000 |
| Currency | USD |
| Employees | 51000 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 3.65 |
| Payout Ratio | 0.18 |
| Current Ratio | 0.95 |
| Quick Ratio | 0.59 |
| Cash Ratio | 0.04 |
Sales & Book Value
| Annual Sales | $321.33B |
| Price / Sales | 0.18 |
| Cash Flow | 8.01 |
| Price / Cash Flow | 37.03 |
| Price / Book | 16.98 |
Price Target and Rating
| Average Stock Price Forecast | $355.00 |
| High Stock Price Forecast | $440.00 |
| Low Stock Price Forecast | $331.00 |
| Forecast Upside/Downside | -16.46% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 46 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $7.96 |
| Trailing P/E Ratio | 22.60 |
| PEG Ratio | 0.44 |
| P/E Growth | 0.44 |
| Net Income | $1.55B |
| Net Margin | 0.78% |
| Pretax Margin | 1.07% |
| Return on Equity | 115.93% |
| Return on Assets | 3.12% |
Financials Score
| AltmanZ Score | 4.74 |
| Piotroski Score | 5.00 |
| Working Capital | -2.99B |
| Total Assets | 81.65B |
| Ebit | 3.96B |
| Market Cap | 58.81B |
| Total Liabilities | 78.07B |
Poll Results
About Cencora, Inc. (NYSE:COR) Stock
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive sup ... port services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
Artisan Mid Cap Fund Q2 2026 Performance Review
2026-07-15 13:56:00
Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.
Carillon Eagle Mid Cap Growth Fund Q2 2026 Portfolio Review
2026-07-14 08:53:00
Carillon Eagle Mid Cap Growth Fund stocks delivered solid results in the second quarter. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions.
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
2026-07-06 13:09:01
Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.
Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release
2026-07-01 16:30:00
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2026 on Wednesday, August 5, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 5, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer Eva C. Boratto, Executive Vice President & Chief.
COR Stock Down Nearly 18% YTD: Should You Buy, Hold or Sell?
2026-06-18 13:50:54
COR shares are down 18% YTD, but rising EPS guidance, specialty pharma growth and strategic expansion could make this pullback worth watching.
Cencora Launches Enhanced Nucleus Solution for Specialty Practices
2026-06-18 11:36:14
COR's enhanced Nucleus platform targets complex specialty medication workflows, with a pilot underway across more than 20 physician practice sites.
Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns
2026-06-18 09:00:50
Rising P/E ratios can signal confidence and momentum. Discover 5 stocks backed by strong earnings growth and upside potential.
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
2026-06-17 09:56:12
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. TPR, VRT, CLS and COR are some such stocks.
Frequently Asked Questions
-
What is the current Cencora, Inc. (COR) stock price?
-
Cencora, Inc.(NYSE:COR) stock price is $296.57 in the last trading session. During the trading session, COR stock reached the peak price of $377.54 while $244.82 was the lowest point it dropped to. The percentage change in COR stock occurred in the recent session was --1.89% while the dollar amount for the price change in COR stock was -$-5.71.
-
COR's industry and sector of operation?
-
The NYSE listed COR is part of Medical - Distribution industry that operates in the broader Healthcare sector.
-
Who are the executives of COR?
-
Bennett S. Murphy | Senior VP Of Investor Relations & Enterprise Productivity and Treasury
François Mandeville | Executive Vice President and Chief Strategy and M&A Officer
Eva C. Boratto | Executive Vice President & Chief Financial Officer
James F. Cleary Jr. | Advisor
Robert Mauch | President, Chief Executive Officer & Director -
How many employees does COR have?
-
Number of COR employees currently stands at 51000. COR operates from 1 West First Avenue, Conshohocken, PA 19428-1800, US.
-
Link for COR official website?
-
Official Website of COR is: https://www.cencora.com
-
How do I contact COR?
-
COR could be contacted at phone #610 727 7000 and can also be accessed through its website. COR operates from 1 West First Avenue, Conshohocken, PA 19428-1800, US.
-
How many shares of COR are traded daily?
-
The average number of COR shares traded daily for last 3 months was 1.83M.
-
What is the market cap of COR currently?
-
The market value of COR currently stands at $57.7B with its latest stock price at $296.57